You are here » Home » Companies » Company Overview » Sequent Scientific Ltd

Sequent Scientific Ltd.

BSE: 512529 Sector: Health care
NSE: SEQUENT ISIN Code: INE807F01027
BSE 00:00 | 06 Oct 111.90 5.95
(5.62%)
OPEN

106.00

HIGH

113.50

LOW

106.00

NSE 00:00 | 06 Oct 111.80 5.80
(5.47%)
OPEN

106.55

HIGH

112.90

LOW

106.15

OPEN 106.00
PREVIOUS CLOSE 105.95
VOLUME 103024
52-Week high 226.50
52-Week low 81.40
P/E 172.15
Mkt Cap.(Rs cr) 2,791
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00
OPEN 106.00
CLOSE 105.95
VOLUME 103024
52-Week high 226.50
52-Week low 81.40
P/E 172.15
Mkt Cap.(Rs cr) 2,791
Buy Price 0.00
Buy Qty 0.00
Sell Price 0.00
Sell Qty 0.00

Sequent Scientific Ltd. (SEQUENT) - Chairman Speech

Company chairman speech

I am excited to be part of the journey that SeQuent has charted for itself which is toemerge as a global animal health major in the coming years.

The Board is bestowed with the role to mentor and help the team in its endeavour.

I am pleased to introduce our newly inducted Board of Directors.

Mr. Milind Sarwate Independent Director has experience in corporate finance valuecreation effective governance and capability building. Mr. Neeraj Bhardwaj Carlylenominee has expertise in large growth capital and buyout opportunities.

Mr. Gregory John Andrews Carlyle nominee has CXO level experience in animal healthfor the developed markets. Mr. Rahul Mukim Carlyle nominee has expertise in buyoutopportunities and healthcare growth investment. Dr. Fabian Kausche Carlyle nominee hasall round expertise in animal health including R&D product innovation and scientificadvisory. I welcome all of them on the SeQuent Board.

The new directors complements the skills and experiences of our current board membersincluding Dr. Kausalya Santhanam Independent Director Mr. Manish Gupta ManagingDirector and Mr. Sharat Narasapur Joint Managing Director and are confident that theywill provide valuable perspectives as we continue to execute our strategy driveprofitability and enhance value for all Sequent's shareholders.

The global animal healthcare market is estimated at US$ 51 billion in 2020 and isforecasted to grow at a CAGR of 5% between 2021 and 2027 led by increasing protein demandand prevalence of animal specific diseases. North America Europe and Latin Americaconstitute a significant portion of the global animal healthcare market. In India thelivestock population contributes 4.5% of India's GDP making it an important factor of therural economy.

I had to start the journey in a most challenging year due to the COVID-19 pandemicwhich caused a scale of suffering that is hard to comprehend. In some parts of the worldthe situation deteriorated further in recent months. The swiftness and intensity of thesecond wave overwhelmed the health systems devastating lives and livelihoods.

It is a health crisis of the kind we have not seen in generations. My heart goes out toeveryone who has suffered the loss of loved ones. Given the scientific progress and theway the pharmaceutical industry has responded I am confident we will eventually be ableto overcome the challenges.

In a challenging environment the leadership team at SeQuent prioritised the health andwell-being of the employees and worked closely to take care of the employees. I would liketo extend my sincere gratitude to SeQuent's go-getters for their commitment towards thebusiness in these trying times. Their dedication enabled us to achieve a creditableperformance in this financial year.

What you see as the SeQuent of today is the result of several well- thought-out bolddecisions taken over the years to transform a diversified business into a global animalhealth company. SeQuent essentially is driving the transformation of a niche industry inIndia. The leadership team built strategic capabilities which include formulations-ledinorganic acquisitions to build front- end presence in key animal health markets ofEurope Brazil and Turkey; and established the only USFDA approved greenfield veterinaryAPI facility in India.

We are now commencing on our next phase of growth internally referenced as SeQuent2.0. SeQuent 2.0 in our opinion is no different from SeQuent 1.0 except that it has abolder ambition led by a strategic global investor and backed by the valuable experienceof a well-diversified board of directors. SeQuent 2.0 we envision will be biggerbolder and more ambitious in the future focusing on growing penetration in existingmarkets while also expanding our scale in newer high-growth geographies.

We will draw upon the distinguished board's experience in scaling businesses to supportentry into new markets and open up opportunities as we embark on the transformationaljourney of Sequent 2.0. This will be in line with the Sequent 2.0 blueprint of enteringkey animal health markets of the USA select EU and South-East Asian markets makinginjectables as the core domain strength in terms of R&D as well as manufacturing andforay into the companion animal or pet business in the select markets of India Turkeyand Brazil. Further strategic partnerships with global animal health companies willelevate SeQuent's relationship to the next level.

Before I sign off I must say that what lies ahead of us is a sea of opportunitieswaiting to be explored and the journey will certainly be an eventful one. I thank theemployees and various stakeholders including bankers customers vendors for supportingthe company so far and look forward to their support in future too. I would also like tothank all the shareholders in reposing their faith and encouraging the management to putout their best.

Warm regards

Dr. Kamal K Sharma

Chairman.

.